These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 39029925)

  • 1. Generation of non-genetically modified, CAR-like, NK cells.
    Coënon L; Rigal E; Courot H; Multrier C; Zemiti S; Lambour J; Pugnière M; de Toledo M; Bossis G; Cartron G; Robert B; Martineau P; Fauvel B; Presumey J; Villalba M
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39029925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. iPSC-derived NK cells expressing high-affinity IgG Fc receptor fusion CD64/16A to mediate flexible, multi-tumor antigen targeting for lymphoma.
    Dixon KJ; Snyder KM; Khaw M; Hullsiek R; Davis ZB; Matson AW; Shirinbak S; Hancock B; Bjordahl R; Hosking M; Miller JS; Valamehr B; Wu J; Walcheck B
    Front Immunol; 2024; 15():1407567. PubMed ID: 39100677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
    Snyder KM; Hullsiek R; Mishra HK; Mendez DC; Li Y; Rogich A; Kaufman DS; Wu J; Walcheck B
    Front Immunol; 2018; 9():2873. PubMed ID: 30574146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity.
    Zhu H; Blum RH; Bjordahl R; Gaidarova S; Rogers P; Lee TT; Abujarour R; Bonello GB; Wu J; Tsai PF; Miller JS; Walcheck B; Valamehr B; Kaufman DS
    Blood; 2020 Feb; 135(6):399-410. PubMed ID: 31856277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. iPSC-derived natural killer cells expressing the FcγR fusion CD64/16A can be armed with antibodies for multitumor antigen targeting.
    Snyder KM; Dixon KJ; Davis Z; Hosking M; Hart G; Khaw M; Matson A; Bjordahl R; Hancock B; Shirinbak S; Miller JS; Valamehr B; Wu J; Walcheck B
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy.
    Guo S; Lei W; Jin X; Liu H; Wang JQ; Deng W; Qian W
    Blood Adv; 2024 Jun; 8(11):2635-2645. PubMed ID: 38564778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia.
    Yang N; Zhang C; Zhang Y; Fan Y; Zhang J; Lin X; Guo T; Gu Y; Wu J; Gao J; Zhao X; He Z
    J Transl Med; 2024 Mar; 22(1):274. PubMed ID: 38475814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
    Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
    Front Immunol; 2019; 10():3123. PubMed ID: 32117200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The human natural killer cytotoxic cell line NK-92, once armed with a murine CD16 receptor, represents a convenient cellular tool for the screening of mouse mAbs according to their ADCC potential.
    Clémenceau B; Vivien R; Pellat C; Foss M; Thibault G; Vié H
    MAbs; 2013; 5(4):587-94. PubMed ID: 23770975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
    Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia.
    Quintarelli C; Sivori S; Caruso S; Carlomagno S; Falco M; Boffa I; Orlando D; Guercio M; Abbaszadeh Z; Sinibaldi M; Di Cecca S; Camera A; Cembrola B; Pitisci A; Andreani M; Vinti L; Gattari S; Del Bufalo F; Algeri M; Li Pira G; Moseley A; De Angelis B; Moretta L; Locatelli F
    Leukemia; 2020 Apr; 34(4):1102-1115. PubMed ID: 31745215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.
    Rosario M; Liu B; Kong L; Collins LI; Schneider SE; Chen X; Han K; Jeng EK; Rhode PR; Leong JW; Schappe T; Jewell BA; Keppel CR; Shah K; Hess B; Romee R; Piwnica-Worms DR; Cashen AF; Bartlett NL; Wong HC; Fehniger TA
    Clin Cancer Res; 2016 Feb; 22(3):596-608. PubMed ID: 26423796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
    Liu E; Tong Y; Dotti G; Shaim H; Savoldo B; Mukherjee M; Orange J; Wan X; Lu X; Reynolds A; Gagea M; Banerjee P; Cai R; Bdaiwi MH; Basar R; Muftuoglu M; Li L; Marin D; Wierda W; Keating M; Champlin R; Shpall E; Rezvani K
    Leukemia; 2018 Feb; 32(2):520-531. PubMed ID: 28725044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-27-engineered CAR.19-NK-92 cells exhibit enhanced therapeutic efficacy.
    Biggi AFB; Silvestre RN; Tirapelle MC; de Azevedo JTC; García HDM; Henrique Dos Santos M; de Lima SCG; de Souza LEB; Covas DT; Malmegrim KCR; Figueiredo ML; Picanço-Castro V
    Cytotherapy; 2024 Nov; 26(11):1320-1330. PubMed ID: 38970613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma.
    Schomer NT; Jiang ZK; Lloyd MI; Klingemann H; Boissel L
    Cytotherapy; 2022 Aug; 24(8):827-834. PubMed ID: 35400595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering of CD34+ progenitor-derived natural killer cells with higher-affinity CD16a for enhanced antibody-dependent cellular cytotoxicity.
    van Hauten PMM; Hooijmaijers L; Vidal-Manrique M; van der Waart AB; Hobo W; Wu J; Blijlevens NMA; Jansen JH; Walcheck B; Schaap NPM; de Jonge PKJD; Dolstra H
    Cytotherapy; 2024 Mar; 26(3):252-260. PubMed ID: 38127030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors.
    Bexte T; Botezatu L; Miskey C; Gierschek F; Moter A; Wendel P; Reindl LM; Campe J; Villena-Ossa JF; Gebel V; Stein K; Cathomen T; Cremer A; Wels WS; Hudecek M; Ivics Z; Ullrich E
    Mol Ther; 2024 Jul; 32(7):2357-2372. PubMed ID: 38751112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
    Oelsner S; Waldmann A; Billmeier A; Röder J; Lindner A; Ullrich E; Marschalek R; Dotti G; Jung G; Große-Hovest L; Oberoi P; Bader P; Wels WS
    Int J Cancer; 2019 Oct; 145(7):1935-1945. PubMed ID: 30860598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19
    Liu Q; Xu Y; Mou J; Tang K; Fu X; Li Y; Xing Y; Rao Q; Xing H; Tian Z; Wang M; Wang J
    Cytotherapy; 2020 Oct; 22(10):552-562. PubMed ID: 32747298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.